中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (10): 892-894.doi: 10.35541/cjd.20210644

• 研究报道 • 上一篇    下一篇

司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察

张婷婷1    朱凤仪1    杨梅2    张平2    夏萍2    周小勇2   

  1. 1湖北中医药大学第一临床学院，武汉  430060；2湖北中医药大学武汉市中西医结合医院皮肤科，武汉  430022
  • 收稿日期:2021-09-03 修回日期:2021-10-18 发布日期:2022-10-08
  • 通讯作者: 夏萍；周小勇 E-mail:445814434@qq.com; zhouxuefeng1970@126.com
  • 作者简介:明年5月份毕业，希望见刊
  • 基金资助:
    湖北省自然科学基金（2020CFB503、2018CFC830）

Clinical efficacy and safety of secukinumab in the treatment of seven cases of erythrodermic psoriasis

Zhang Tingting1, Zhu Fengyi1, Yang Mei2, Zhang Ping2, Xia Ping2, Zhou Xiaoyong2   

  1. 1The First Clinical Medical School of Hubei University of Chinese Medicine, Wuhan 430060, China; 2Department of Dermatology, Wuhan Hospital of Integrated Traditional Chinese and Western Medicine, Wuhan 430022, China
  • Received:2021-09-03 Revised:2021-10-18 Published:2022-10-08
  • Contact: Xia Ping; Zhou Xiaoyong E-mail:445814434@qq.com; zhouxuefeng1970@126.com
  • Supported by:
    Natural Science Foundation of Hubei Province（2020CFB503、2018CFC830）

PDF

65

PDF (Mobile)

11

摘要： 【摘要】 目的 观察司库奇尤单抗治疗红皮病型银屑病的临床疗效及安全性。方法 2019年7月至2021年8月就诊于武汉市中西医结合医院的红皮病型银屑病并接受司库奇尤单抗（300 mg/次皮下注射，分别于第0、1、2、3、4周注射1次，随后每4周1次）治疗的7例患者，在第0、 4、 8、12周时记录患者银屑病皮损面积和严重度指数（PASI），同时观察药物不良反应。结果 7例患者均接受至少12周的治疗，治疗4周时，4例达到PASI50；治疗12周，4例达到PASI75，2例达到PASI90。均未发生严重药物不良反应，1例治疗过程中出现发热，用药后体温恢复正常；1例出现咳嗽咳痰，予以口服咽炎合剂后症状缓解。结论 司库奇尤单抗治疗红皮病型银屑病疗效显著，不良反应较少，为红皮病型银屑病的治疗提供了新的选择。

关键词: 银屑病, 治疗结果, 生物制剂, 红皮病型, 司库奇尤单抗

Abstract: 【Abstract】 Objective To evaluate clinical efficacy and safety of secukinumab in the treatment of erythrodermic psoriasis. Methods From July 2019 to August 2021, 7 patients with erythrodermic psoriasis, who received subcutaneous injection of secukinumab at a dose of 300 mg once a week from week 0 to 4 followed by every-4-week dosing in Wuhan Hospital of Integrated Traditional Chinese and Western Medicine, were collected. At weeks 0, 4, 8 and 12, the psoriasis area and severity index （PASI） was recorded, and adverse drug reactions were observed. Results All 7 patients were treated for at least 12 weeks. After 4-week treatment, 4 patients achieved PASI50; after 12-week treatment, 5 achieved PASI75, and 2 achieved PASI90. No serious adverse drug reactions occurred. One patient developed fever during the treatment, but the body temperature returned to normal after management; another 1 developed cough and expectoration, and the symptoms were relieved after oral administration of a Chinese herbal preparation named pharyngitis mixture. Conclusion Secukinumab is effective in the treatment of erythrodermic psoriasis, with fewer adverse reactions, which provides a new option for the treatment of erythrodermic psoriasis.

Key words: Psoriasis, Treatment outcome, Biological agents, Erythrodermic, Secukinumab